pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
GLP-1 receptor · news · pharmadog
← back to GLP-1 receptor
News · GLP-1 receptor
471
stories
Sep 30, 26
STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial
stat
Sep 30, 26
Lilly builds commercial case for GLP-1 products over Novo with indirect analyses
biospace
Sep 30, 26
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
fiercebiotech
Sep 30, 26
Lilly sets up next-gen obesity battle with full phase 3 retatrutide data
fiercebiotech
Sep 29, 26
Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill
biopharma dive
Sep 29, 26
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
biospace
Sep 29, 26
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
stat
Sep 29, 26
After GLP-1s, biosimilars are the new frontier in direct-to-employer plans
endpoints
Sep 29, 26
Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal
biospace
Sep 29, 26
Novo to spend $300M upfront to license Hengrui's weekly oral weight loss drug
endpoints
Sep 29, 26
Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui
fiercebiotech
Sep 28, 26
Roche cans muscle-preserving obesity drug, hands it back to Chugai
endpoints
Sep 28, 26
STAT+: AbbVie wins FDA nod for Parkinson’s pill
stat
Sep 28, 26
STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more
stat
Sep 28, 26
Trump uses ‘contested’ power to cut more funding to HHS
stat
Sep 28, 26
Roche drops muscle-sparing obesity antibody after flunked interim analysis
fiercebiotech
Sep 28, 26
STAT+: Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’
stat
Sep 28, 26
CDER director, expert discuss scientific, legal challenges to bringing generic GLP-1s to market
raps
Sep 25, 26
This week in charts: Novo’s rise and fall and AI biotechs’ big haul
biopharma dive
Sep 25, 26
Novo inks $1.3B Nanexa deal to unlock long-acting obesity injectables
fiercebiotech
Sep 24, 26
Pioneer of China NewCo model sued in US over trade secret misuse, double-dealing
fiercebiotech
Sep 24, 26
FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’
biospace
Sep 24, 26
Eli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalry
biospace
Sep 24, 26
Lilly puts up $100M, plus billions on the backend, to form 5-target deal with China's InnoCare
fiercebiotech
Sep 23, 26
Enveda, an AI drugmaker, banks $311M in venture funding
biopharma dive
Sep 23, 26
AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease push
biospace
Sep 23, 26
STAT+: Pharmalittle: We’re reading about a closing loophole for importing meds, European competitiveness, and more
stat
Sep 23, 26
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
biospace
Sep 22, 26
Compounder Empower receives FDA warning letter over GLP-1s
endpoints
Sep 22, 26
Viking shares surge on updated obesity drug data
biopharma dive
← prev
page 6 of 16
next →